Entry
Name
Non-alcoholic fatty liver disease - Homo sapiens (human)
Description
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum ranging from simple steatosis to more severe steatohepatitis with hepatic inflammation and fibrosis, known as nonalcoholic steatohepatitis (NASH). NASH may further lead to cirrhosis and hepatocellular carcinoma (HCC). This map shows a stage-dependent progression of NAFLD. In the first stage of NAFLD, excess lipid accumulation has been demonstrated. The main cause is the induction of insulin resistance, which leads to a defect in insulin suppression of free fatty acids (FAAs) disposal. In addition, two transcription factors, SREBP-1c and PPAR-alpha, activate key enzymes of lipogenesis and increase the synthesis of FAAs in liver. In the second stage, as a consequence of the progression to NASH, the production of reactive oxygen species (ROS) is enhanced due to oxidation stress through mitochondrial beta-oxidation of fatty acids and endoplamic reticulum (ER) stress, leading to lipid peroxidation. The lipid peroxidation can further cause the production of cytokines (Fas ligand, TNF-alpha, IL-8 and TGF), promoting cell death, inflammation and fibrosis. The activation of JNK, which is induced by ER stress, TNF-alpha and FAAs, is also associated with NAFLD progression. Increased JNK promotes cytokine production and initiation of HCC.
Class
Human Diseases; Endocrine and metabolic disease
BRITE hierarchy
Pathway map
hsa04932 Non-alcoholic fatty liver disease
Ortholog table
Disease
H01333 Non-alcoholic fatty liver disease
Drug
D10988 Selonsertib (JAN/USAN/INN)
D11257 Seladelpar lysine (USAN)
Organism
Homo sapiens (human) [GN:
hsa ]
Gene
9021 SOCS3; suppressor of cytokine signaling 3 [KO:K04696 ]
7132 TNFRSF1A; TNF receptor superfamily member 1A [KO:K03158 ]
4790 NFKB1; nuclear factor kappa B subunit 1 [KO:K02580 ]
5970 RELA; RELA proto-oncogene, NF-kB subunit [KO:K04735 ]
3667 IRS1; insulin receptor substrate 1 [KO:K16172 ]
8660 IRS2; insulin receptor substrate 2 [KO:K07187 ]
5290 PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922 ] [EC:2.7.1.153 ]
5293 PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922 ] [EC:2.7.1.153 ]
5291 PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922 ] [EC:2.7.1.153 ]
5295 PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649 ]
5296 PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649 ]
8503 PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649 ]
10062 NR1H3; nuclear receptor subfamily 1 group H member 3 [KO:K08536 ]
6720 SREBF1; sterol regulatory element binding transcription factor 1 [KO:K07197 ]
6945 MLX; MAX dimerization protein MLX [KO:K09113 ]
9370 ADIPOQ; adiponectin, C1Q and collagen domain containing [KO:K07296 ]
5564 PRKAB1; protein kinase AMP-activated non-catalytic subunit beta 1 [KO:K07199 ]
5565 PRKAB2; protein kinase AMP-activated non-catalytic subunit beta 2 [KO:K07199 ]
5571 PRKAG1; protein kinase AMP-activated non-catalytic subunit gamma 1 [KO:K07200 ]
53632 PRKAG3; protein kinase AMP-activated non-catalytic subunit gamma 3 [KO:K07200 ]
51422 PRKAG2; protein kinase AMP-activated non-catalytic subunit gamma 2 [KO:K07200 ]
5465 PPARA; peroxisome proliferator activated receptor alpha [KO:K07294 ]
5468 PPARG; peroxisome proliferator activated receptor gamma [KO:K08530 ]
998 CDC42; cell division cycle 42 [KO:K04393 ]
2081 ERN1; endoplasmic reticulum to nucleus signaling 1 [KO:K08852 ] [EC:2.7.11.1 3.1.26.-]
2353 FOS; Fos proto-oncogene, AP-1 transcription factor subunit [KO:K04379 ]
3725 JUN; Jun proto-oncogene, AP-1 transcription factor subunit [KO:K04448 ]
1050 CEBPA; CCAAT enhancer binding protein alpha [KO:K09055 ]
1571 CYP2E1; cytochrome P450 family 2 subfamily E member 1 [KO:K07415 ] [EC:1.14.14.-]
3576 CXCL8; C-X-C motif chemokine ligand 8 [KO:K10030 ]
7040 TGFB1; transforming growth factor beta 1 [KO:K13375 ]
9451 EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 [KO:K08860 ] [EC:2.7.11.1 ]
1965 EIF2S1; eukaryotic translation initiation factor 2 subunit alpha [KO:K03237 ]
468 ATF4; activating transcription factor 4 [KO:K04374 ]
1649 DDIT3; DNA damage inducible transcript 3 [KO:K04452 ]
581 BAX; BCL2 associated X, apoptosis regulator [KO:K02159 ]
355 FAS; Fas cell surface death receptor [KO:K04390 ]
637 BID; BH3 interacting domain death agonist [KO:K04726 ]
4731 NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 [KO:K03944 ]
4694 NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 [KO:K03945 ]
4695 NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 [KO:K03946 ]
4696 NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 [KO:K03947 ]
4697 NDUFA4; NDUFA4 mitochondrial complex associated [KO:K03948 ]
56901 NDUFA4L2; NDUFA4 mitochondrial complex associated like 2 [KO:K03948 ]
4698 NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 [KO:K03949 ]
4700 NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 [KO:K03950 ]
4701 NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 [KO:K03951 ]
4702 NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 [KO:K03952 ]
4704 NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 [KO:K03953 ]
4705 NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 [KO:K03954 ]
4706 NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 [KO:K03955 ]
126328 NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 [KO:K03956 ]
55967 NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 [KO:K11352 ]
51079 NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 [KO:K11353 ]
4707 NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 [KO:K03957 ]
4708 NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 [KO:K03958 ]
4709 NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 [KO:K03959 ]
4710 NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 [KO:K03960 ]
4711 NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 [KO:K03961 ]
4712 NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 [KO:K03962 ]
4713 NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 [KO:K03963 ]
4714 NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 [KO:K03964 ]
4715 NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 [KO:K03965 ]
4716 NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 [KO:K03966 ]
54539 NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 [KO:K11351 ]
4724 NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 [KO:K03937 ]
4725 NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 [KO:K03938 ]
4726 NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 [KO:K03939 ]
4717 NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 [KO:K03967 ]
4718 NDUFC2; NADH:ubiquinone oxidoreductase subunit C2 [KO:K03968 ]
6389 SDHA; succinate dehydrogenase complex flavoprotein subunit A [KO:K00234 ] [EC:1.3.5.1 ]
6390 SDHB; succinate dehydrogenase complex iron sulfur subunit B [KO:K00235 ] [EC:1.3.5.1 ]
6391 SDHC; succinate dehydrogenase complex subunit C [KO:K00236 ]
6392 SDHD; succinate dehydrogenase complex subunit D [KO:K00237 ]
7386 UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 [KO:K00411 ] [EC:7.1.1.8 ]
7384 UQCRC1; ubiquinol-cytochrome c reductase core protein 1 [KO:K00414 ]
7385 UQCRC2; ubiquinol-cytochrome c reductase core protein 2 [KO:K00415 ]
7388 UQCRH; ubiquinol-cytochrome c reductase hinge protein [KO:K00416 ]
440567 UQCRHL; ubiquinol-cytochrome c reductase hinge protein like [KO:K00416 ]
7381 UQCRB; ubiquinol-cytochrome c reductase binding protein [KO:K00417 ]
27089 UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII [KO:K00418 ]
29796 UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X [KO:K00419 ]
10975 UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI [KO:K00420 ]
4514 COX3; cytochrome c oxidase subunit III [KO:K02262 ]
4513 COX2; cytochrome c oxidase subunit II [KO:K02261 ]
84701 COX4I2; cytochrome c oxidase subunit 4I2 [KO:K02263 ]
1327 COX4I1; cytochrome c oxidase subunit 4I1 [KO:K02263 ]
9377 COX5A; cytochrome c oxidase subunit 5A [KO:K02264 ]
1329 COX5B; cytochrome c oxidase subunit 5B [KO:K02265 ]
1337 COX6A1; cytochrome c oxidase subunit 6A1 [KO:K02266 ]
1339 COX6A2; cytochrome c oxidase subunit 6A2 [KO:K02266 ]
1340 COX6B1; cytochrome c oxidase subunit 6B1 [KO:K02267 ]
1345 COX6C; cytochrome c oxidase subunit 6C [KO:K02268 ]
1346 COX7A1; cytochrome c oxidase subunit 7A1 [KO:K02270 ]
1347 COX7A2; cytochrome c oxidase subunit 7A2 [KO:K02270 ]
9167 COX7A2L; cytochrome c oxidase subunit 7A2 like [KO:K02270 ]
1349 COX7B; cytochrome c oxidase subunit 7B [KO:K02271 ]
1350 COX7C; cytochrome c oxidase subunit 7C [KO:K02272 ]
1351 COX8A; cytochrome c oxidase subunit 8A [KO:K02273 ]
Compound
Reference
Authors
Naik A, Kosir R, Rozman D
Title
Genomic aspects of NAFLD pathogenesis.
Journal
Reference
Authors
Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L
Title
Molecular mechanisms involved in NAFLD progression.
Journal
Reference
Authors
Seki E, Brenner DA, Karin M
Title
A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches.
Journal
Reference
Authors
Tilg H, Moschen AR
Title
Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis.
Journal
Reference
Authors
Larter CZ, Farrell GC
Title
Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?
Journal
Reference
Authors
Farrell GC, van Rooyen D, Gan L, Chitturi S
Title
NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.
Journal
Reference
Authors
Shapiro H, Tehilla M, Attal-Singer J, Bruck R, Luzzatti R, Singer P
Title
The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease.
Journal
Reference
Authors
Hotamisligil GS
Title
Endoplasmic reticulum stress and the inflammatory basis of metabolic disease.
Journal
Reference
Authors
Parekh S, Anania FA
Title
Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease.
Journal
Reference
Authors
Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, Czaja MJ
Title
JNK1 but not JNK2 promotes the development of steatohepatitis in mice.
Journal
Reference
Authors
Leung TM, Nieto N
Title
CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease.
Journal
Reference
Authors
Zafrani ES
Title
Non-alcoholic fatty liver disease: an emerging pathological spectrum.
Journal
Reference
Authors
Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ
Title
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis.
Journal
Reference
Authors
Begriche K, Igoudjil A, Pessayre D, Fromenty B
Title
Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.
Journal
Reference
Authors
Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, Dargel R, Poli G
Title
The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor beta1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis.
Journal
Reference
Authors
Malhi H, Kaufman RJ
Title
Endoplasmic reticulum stress in liver disease.
Journal
Reference
Authors
Mantena SK, King AL, Andringa KK, Eccleston HB, Bailey SM
Title
Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases.
Journal
Reference
Authors
Serviddio G, Sastre J, Bellanti F, Vina J, Vendemiale G, Altomare E
Title
Mitochondrial involvement in non-alcoholic steatohepatitis.
Journal
Reference
Authors
Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B
Title
Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease.
Journal
Related pathway
hsa04141 Protein processing in endoplasmic reticulum
hsa04920 Adipocytokine signaling pathway
KO pathway